Experiences with
Acalabrutinib558 public posts
Want to take advantage of all our features? Just log in!
or
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
Estimated 36-month overall survival was 94.1% with acalabrutinib–venetoclax, 87.7% with acalabrutinib–venetoclax–obinutuzumab, and 85.9% with chemoimmunotherapy.
UK Telegraph Newspaper report
He received treatment in the UK STELLAR trial which adds Acalabrutinib to the usual R-CHOP chemotherapy. He's had a spectacular response and his story is here
http://digitaleditions.telegraph.co.uk/data/1838/reader/reader.html?social#!
Why does ibrutinib cause nail brittleness (onychorrhexis and onychoschizia) or curly hair in some CLL patients? What can you do about it?
/efficacy-and-safety-of-new%E2%80%91generation-btkis-primarily-acalabrutinib-and-zanubrutinib-in-cll-sll-a-systematic-review-and-meta%E2%80%91analysis[/i]
[i]Largest real world study of and ibrutinib over 3 years, shows acalabrutinib has improved discontinuation rates[/i]
[i]https